Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer's disease.
Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, Kondo T, Abe K, Xiao JZ. · 2017
Read Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer's disease. by Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, Kondo T, Abe K, Xiao JZ. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5647431.txt.
Description
Kobayashi and co-authors report a mouse study in Scientific Reports. It tests a probiotic strain against Alzheimer's-type decline. The strain is Bifidobacterium breve A1. Mice got amyloid-beta injections to model the disease. Daily oral doses of the bacterium followed. Behavior tests checked memory and learning.
Treated mice kept normal alternation behavior in a Y maze. Their passive avoidance performance also held up. The authors report that this means cognitive dysfunction was prevented. Dead bacterial parts and acetate each helped in part. Gene profiling showed lower inflammation gene activity in the hippocampus. Amyloid-beta normally raises those genes. The findings suggest value in gut-brain approaches to prevention.
Catalog record
| CREATOR | Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, Kondo T, Abe K, Xiao JZ. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |